Thorne Healthtech Inc THRN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$10.19 unchanged at close Oct 16
Last close · Previous close $10.19
- Market cap
- At the Oct 16 close
- P/E ratio
- 26.82On last 12 months’ EPS
- Diluted EPS
- $0.38Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$10.19unchangedPast month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$10.19Oct 13
- Volume0.00Oct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume192.31KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | THRN |
|---|---|
| Short term | |
| 1M | THRN: unchanged |
| 3M | THRN: up 106.7% |
| YTD | THRN: up 180.7% |
| 1Y | THRN: up 121.5% |
$10,000 invested in THRN a year ago (Oct 14, 2022) would be worth about $22,152 at the close on , with dividends reinvested.
| Period | THRN |
|---|---|
| Short term | |
| 1M | THRN: unchanged |
| 3M | THRN: up 106.7% |
| YTD | THRN: up 180.7% |
| 1Y | THRN: up 121.5% |
$10,000 invested in THRN a year ago (Oct 14, 2022) would be worth about $22,152 at the close on , not counting dividends.
All-time high
$10.20
Closing high on . Now 0.1% below that record.
Split-adjusted daily closes since Sep 23, 2021.
Stock splits
THRN hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY23, the quarter ended Jun 30, 2023. “Last 12 months” means the four quarters from Jul 1, 2022 to Jun 30, 2023, and balance-sheet figures are as of Jun 30, 2023.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $255.95Mup 24.5%
- Net income
- $20.33Mup 904.7%
- Diluted EPS
- $0.38up 375.0%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY21 (Sep 30, 2021) | $48.01M | $1.03M | $0.01 |
| Q4 FY21 (Dec 31, 2021) | $48.92M | $1.61M | $0.09 |
| Q1 FY22 (Mar 31, 2022) | $54.03M | $4.98M | $0.09 |
| Q2 FY22 (Jun 30, 2022) | $54.64M | −$5.59M | −$0.11 |
| Q3 FY22 (Sep 30, 2022) | $58.42M | $3.74M | $0.07 |
| Q4 FY22 (Dec 31, 2022) | $59.58M | $12.55M | $0.24 |
| Q1 FY23 (Mar 31, 2023) | $65.24M | −$402.16K | −$0.01 |
| Q2 FY23 (Jun 30, 2023) | $72.71M | $4.45M | $0.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $138.45M | −$3.36M | −$0.34 |
| FY21 (Dec 31, 2021) | $184.30M | $7.25M | $0.10 |
| FY22 (Dec 31, 2022) | $228.73M | $15.67M | $0.30 |
Margins
- Gross 50.2%
- Operating 5.3%
- Net 7.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$14.32MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$21.52MLast 12 months
- Capital spending$35.84MLast 12 months
- −5.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.83MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$1.83MLast 12 months
Balance sheet
- $34.68MAs of Jun 30, 2023
Cash plus short- and long-term marketable securities on the Jun 30, 2023 balance sheet.
- Total debt$74.73MAs of Jun 30, 2023
- Net debt$40.05MAs of Jun 30, 2023
- 2.41As of Jun 30, 2023
Current assets divided by current liabilities on the Jun 30, 2023 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.49As of Jun 30, 2023
Total debt divided by shareholders’ equity on the Jun 30, 2023 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 14.1%Last 12 months
Over the last 12 months, Thorne Healthtech’s net income was 14.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 8.6%Last 12 months
Over the last 12 months, Thorne Healthtech’s net income was 8.6% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Thorne Healthtech Inc
Thorne Healthtech Inc
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Headquarters
- South Carolina, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
THRN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
THRN stock FAQ
What is THRN stock’s price today?
Thorne Healthtech (THRN) traded at $10.19 at the close on , unchanged from the previous close of $10.19.
What is THRN’s P/E ratio?
THRN trades at 26.8 times its diluted earnings over the four quarters to ($0.38 per share), at the close. (How the P/E ratio works.)
How much revenue does Thorne Healthtech make?
Thorne Healthtech reported $255.9 million of revenue over the four quarters to , up 24.5% from the twelve months before. In its latest quarter (Q2 FY23, ended ) revenue was $72.7 million, up 33.1% from a year earlier.
Is Thorne Healthtech profitable?
Yes. Thorne Healthtech earned $20.3 million of net income over the four quarters to , a net margin of 7.9%, and its operating margin was 5.3% (what margins tell you).
What are THRN’s earnings per share?
THRN’s diluted earnings per share were $0.38 over the four quarters to , compared with $0.08 in the twelve months before. The latest quarter (Q2 FY23) brought $0.08 per share, against −$0.11 a year earlier (how EPS works).
Does THRN pay a dividend?
Thorne Healthtech hasn’t paid a dividend in the last twelve months.
What is THRN’s all-time high?
THRN’s highest closing price was $10.20 on , adjusted for stock splits. At $10.19 at the close on , it is 0.1% below that record.
Has THRN stock ever split?
No. THRN hasn’t split since its price history begins in 2021.
How has THRN stock performed?
Including dividends and measured to the close on , THRN has returned +180.7% so far this year and +121.5% over the past year. Past performance doesn’t predict future returns.
What sector and industry is Thorne Healthtech in?
Thorne Healthtech is in the Consumer Defensive sector and the Packaged Foods industry, and is headquartered in South Carolina, USA.
What exchange does THRN trade on?
Thorne Healthtech trades on the Nasdaq under the ticker symbol THRN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.